Eli Lilly (NY:LLY)

Eli Lilly continues to pursue smart acquisitions for the long term.

What Is One of the Best Pharmaceutical Stocks to Own for the Next 10 Years? ↗

February 14, 2026

Topics Intellectual Property

Got $500? 2 Pharma Stocks to Buy and Hold Forever. ↗

February 14, 2026

Growth, value, or both?

Novo Nordisk To Meet Wegovy Pill Demand In US Before Expanding To Avoid Supply Shortage, Says CEO Doustdar ↗

February 13, 2026

Novo is looking to ensure the U.S. market is supplied before choosing another country to scale in, Doustdar said in an interview with CNBC.

The U.S. labor market kicked off 2026 with an unexpected surge, as the January nonfarm payrolls report shattered analyst expectations and provided a much-needed jolt to the economic outlook. Adding...

Topics Lawsuit

"Blowout" Jobs Report Ignites 2026 Growth Hopes as Unemployment Hits 4.3% Floor

February 13, 2026

Hospitals Stand Tall: Healthcare Sector Becomes Safe Haven Amid "Warsh Shock" and Tech Volatility

Topics Artificial Intelligence Economy Workforce

February 13, 2026

In a day defined by sharp reversals and a fundamental recalibration of market leadership, the healthcare sector emerged as the primary beneficiary of a massive capital rotation on February 13, 2026....

Eli Lilly announced an acquisition of an innovative new autoimmune drug.

Topics Artificial Intelligence Earnings Economy

Did Eli Lilly Just Make a Deal for Its Next Blockbuster Drug? ↗

February 13, 2026

The Great 2026 Divergence: Tech Titans Rise on AI Execution While Healthcare Reaps a Regulatory Whirlwind

February 13, 2026

As the opening bell rang on February 13, 2026, the divergence between the U.S. technology and healthcare sectors reached a historic fever pitch, signaling a fundamental shift in how markets price...

Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.

Topics Artificial Intelligence Economy Intellectual Property

Meet the 6.3% Yield Dividend Stock That Could Soar in 2026 ↗

February 13, 2026

Eli Lilly Builds $1.5 Billion Inventory Of Experimental Weight-Loss Pill As FDA Decision Looms ↗

Topics Intellectual Property

February 13, 2026

Eli Lilly and Company (NYSE: LLY) has stockpiled $1.5 billion worth of inventory of its experimental oral weight-loss drug, orforglipron, according to a regulatory filing on Thursday.

Via Benzinga

Nasdaq, S&P 500 Futures Edge Lower Ahead Of CPI Data: Why NVDA, AAPL, TSLA, RIVN, MRNA, AMAT, IREN Are On Traders' Radar Today ↗

February 13, 2026

Data on Stocktwits showed retail traders remained bearish on SPY and ‘extremely bearish’ on QQQ.

Meta Platforms Breaks Ground on Massive $10 Billion Indiana Data Center: A Giant Leap Toward 'Personal Superintelligence'

Topics Bonds ETFs Economy

February 12, 2026

On February 11, 2026, Meta Platforms Inc. (NASDAQ: META) officially broke ground on a sprawling $10 billion data center campus in Lebanon, Indiana, marking a monumental shift in the company’s...

As of February 12, 2026, the financial landscape has undergone a tectonic shift, with the healthcare sector decisively seizing the mantle of market leadership. After years of dominance by high-flying...

Topics Artificial Intelligence Earnings Economy

The Great Rotation: Healthcare Emerges as the S&P 500’s New Crown Jewel in 2026

February 12, 2026

Novo Nordisk Plans Wegovy Vial Launch To Counter Eli Lilly, Target Broader Obesity Market ↗

Topics Artificial Intelligence Bonds Economy

February 12, 2026

Novo Nordisk plans to sell Wegovy in vials in the U.S., expanding options as it competes with Eli Lilly in the growing weight-loss drug market.

Via Benzinga

Healthcare’s Renaissance: Sector Outshines Tech as Policy Clarity Sparks Q4 Surge

February 12, 2026

The healthcare sector has staged a dramatic structural breakout, ending a multi-year period of relative stagnation to lead the global markets into 2026. After a powerful 10% gain in the final quarter...

Goldman Sachs Predicts 12% S&P 500 Rally in 2026: Five Key Themes for the "Marathon" Bull Market

Topics Artificial Intelligence Economy World Trade

February 12, 2026

As the global economy stabilizes into a period of disinflationary growth, Goldman Sachs (NYSE: GS) has released a robust 2026 stock market outlook, forecasting a 12% total return for the S&P 500. This...

Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know. ↗

Topics Artificial Intelligence Economy Initial Public Offering

February 12, 2026

Both companies are betting on interest in weight loss pills.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

1 Cash-Producing Stock with Competitive Advantages and 2 That Underwhelm

February 11, 2026

I Predicted That ExxonMobil Would Join the $1 Trillion Club by 2030, But the Stock Is Already Up 24% in 2026. Is the High-Yield Dividend Stock Still a Buy Now? ↗

February 11, 2026

Energy stocks are in the spotlight, and ExxonMobil is best in breed.

The company shared optimistic timelines for advancing the clinical studies of both oral and subcutaneous VK2735 in obesity.

Topics Artificial Intelligence

VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline ↗

February 11, 2026

Novo Nordisk Reportedly Eyes Launching Wegovy In Vials To Compete With Rival Eli Lilly ↗

February 11, 2026

Bloomberg reported on Wednesday, citing Novo CEO Mike Doustdar, that the vials are slated to be introduced in the U.S. this year.

The healthcare leader looks increasingly unstoppable.

Topics Intellectual Property

3 Reasons to Buy Eli Lilly Stock ↗

February 11, 2026

Disney has hired a new CEO, with Josh D'Amaro taking over for Bob Iger in March.

Topics Government

Disney Has Its Next CEO ↗

February 11, 2026

Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two high-yield healthcare stocks.

Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip. ↗

February 11, 2026

Big pharma and biotech take the earnings stage with reports from Eli Lilly and Novo Nordisk leading the lineup. Will they help the industry once again outperform AI champ Nvidia?

Biotech Beat Nvidia in 2025. Can It Do It Again? ↗

February 11, 2026

As of February 11, 2026, Incyte Corporation (NASDAQ: INCY) finds itself at a pivotal crossroads. Known for over a decade as a one-drug powerhouse centered on the hematology blockbuster Jakafi, the...

Topics Artificial Intelligence

Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss

February 11, 2026

Via Finterra

Topics Economy Intellectual Property

Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore ↗

February 11, 2026

This stock has been known to soar after good news.

Eli Lilly's fourth quarter performance was defined by accelerating demand for its obesity and diabetes medicines, as well as rapid uptake in international markets. Management highlighted the strong...

The Top 5 Analyst Questions From Eli Lilly’s Q4 Earnings Call

February 11, 2026

Animal health company Zoetis (NYSE:ZTS) will be announcing earnings results this Thursday morning. Here’s what to expect.

Topics Earnings

Zoetis (ZTS) Reports Q4: Everything You Need To Know Ahead Of Earnings

February 10, 2026

Pharmaceutical company Organon (NYSE:OGN) will be announcing earnings results this Thursday morning. Here’s what you need to know.

Topics Artificial Intelligence

Organon Earnings: What To Look For From OGN

February 10, 2026